Aging in down syndrome and the development of Alzheimer’s disease neuropathology

Current Alzheimer Research

Volumn 13, Issue 1, 2016, Pages 18-29

  Head, Elizabeth ^a   Lott, Ira T ^b   Wilcock, Donna M ^a   Lemere, Cynthia A ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Beta amyloid; Neurofibrillary tangles; Neuroinflammation; Oxidative damage; Posttranslational modifications; Senile plaques; Trisomy 21; Vascular pathology; White matter damage

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; OLIGOMER; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN; CELL LOSS; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CLEARANCE; DOWN SYNDROME; GENE OVEREXPRESSION; HUMAN; NERVE CELL; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROMUSCULAR SYNAPSE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; WHITE MATTER; AGE; ANIMAL; GENETICS; METABOLISM; MICROBIOLOGY; PATHOLOGY;

AGE FACTORS; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DOWN SYNDROME; HUMANS; NEUROFIBRILLARY TANGLES; NEUROPATHOLOGY; TAU PROTEINS;

EID: 84953440007     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666151020114607     Document Type: Article

References (159)

1. Down JLH. Observations on ethnic classification of idiots. Lond Hosp Rep 3: 259-62 (1866).
2. Lejeune J, Gautier M, Turpin R. Etude des chromosomes somatiques de neuf enfants mongoliens. Comptes Rendus Hebdomadaires des Seances de L'Academie des Sciences 248: 1721-22 (1959).
3. Roizen NJ, Patterson D. Down's syndrome. Lancet 361(9365): 1281-9 (2003).
4. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 9(6): 623-33 (2010).
5. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genetx 62(5): 390-3 (2002).
6. Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur J Public Health 17(2): 221-5 (2007).
7. Strauss D, Eyman RK Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991. Am J Ment Retard 100(6): 643-53 (1996).
8. Zigman WB. Atypical aging in down syndrome. Dev Disabil Res Rev 18(1): 51-67 (2013).
9. Hartley D, lumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, et al. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement 11(6): 700-9 (2015).
10. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, et al. Amyloid A4 and its precursor in Down's syndrome and Alzheimer's disease. New Engl J Med 320: 1446-62 (1989).
11. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's diase. Nature 333: 528-530 (1988).
12. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388(6645): 878-81 (1997).
13. Nunan J, Small DH. Regulation of APP cleavage by a-, b-and gsecretases. FEBS Lett 483: 6-10 (2000).
14. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17: 489-517 (1994).
15. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735-41 (1999).
16. Nistor M, Don M, Parekh M, Sarsoza F, Goodus M, Lopez GE, et al. Alpha-and beta-secretase activity as a function of age and betaamyloid in Down syndrome and normal brain. Neurobiol Aging 28(10): 1493-506 (2007).
17. Miners JS, Morris S, Love S, Kehoe PG. Accumulation of insoluble amyloid-beta in down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimers Dis 23(1): 101-8 (2011).
18. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, et al. BACE2 expression increases in human neurodegenerative disease. Am J Pathol 180(1): 337-50 (2012).
19. Webb RL, Murphy MP. beta-Secretases, Alzheimer's Disease, and Down Syndrome. Curr Gerontol Geriatr Res 2012: 362839 (2012).
20. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci 16(5): 609-19 (2000).
21. Barbiero L, Benussi L, Ghidoni R, Alberici A, Russo C, Schettin G, et al. BACE-2 is overexpressed in Down's syndrome. Exp Neurol 182: 335-45 (2003).
22. Motonaga K, Itoh, M, Becker LE, Goto Y, Takashima S. Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome. Neurosci Lett 326: 64-6 (2002).
23. Cheon MS, Dierssen M, Kim SH, Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids 35(2): 339-43 (2008).
24. Head E, Lott IT. Down syndrome and beta-amyloid deposition. Curr Opin Neurol 17(2): 95-100 (2004).
25. Teller JK, Russo C, DeBusk LM, Angelini G, Zacceo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid b-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2(1): 93-5 (1996).
26. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ, et al., Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30(4): 552-7 (2002).
27. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al., Diffusable, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95: 6448-53 (1998).
28. Cummings BJ. Plaques and tangles: searching for primary events in a forest of data. Neurobiol Aging 18(4): 358-62 (1997).
29. Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX, et al. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis 22(2): 393-9 (2010).
30. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in APP23 model precedes amyloid deposition. Eur J Neurosci 17: 388-96 (2003).
31. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Ab and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22(5): 1858-67 (2002).
32. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880): 535-9 (2002).
33. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble Ab(N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271: 4077-4081 (1996).
34. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489 (2003).
35. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: Presence of oligomeric Ab ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci 100(18): 10417-10422 (2003).
36. Cenini, G., et al. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822(2): 130-8 (2012).
37. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal Ab-Amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489-492 (2001).
38. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, et al., Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9(2): 88-102 (2002).
39. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, et al., Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156(1): 15-20 (2000).
40. Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S. Characteristic developmental expression of amyloid b40, 42 and 43 in patients with Down syndrome. Brain Develop 25: 180-5 (2003).
41. Knauer MF, Soreghan B, Burdick D, Kosmoski J, Glabe CG. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci USA 89(16): 7437-41 (1992).
42. Yang AJ, Chandswangbhuvana D, Shu T, Henschen A, Glabe CG. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J Biol Chem 274(29): 20650-6 (1999).
43. Glabe, C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's Disease. J Mol Neurosci 17: 137-145 (2001).
44. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Ab and synaptic dysfunction. Neuron 39: 409-421 (2003).
45. Wirth O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, et al. Intraneuronal Ab accumulation precedes plaque formation in b-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 306: 116-120 (2001).
46. Head E, Lott IT, Cribbs DH, Cotman CW, Rohn TT. Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Neurosci Lett 330(1): 99-103 (2002).
47. Mann DMA, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89: 169-179 (1989).
48. Wisniewski K, Howe J, Williams G, Wisniewski HM. Precocious aging and dementia in patients with Down's syndrome. Biological Psychiatry 13(5): 619-627 (1978).
49. Wisniewski K, Wisniewski H, Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17: 278-282 (1985).
50. Head E, Powell D, Gold BT, Schmitt FA. Alzheimer's disease in Down syndrome. European Journal of Neurodegenerative Dis 1(3): 353-364 (2012).
51. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
52. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38(1): 24-6 (2006).
53. Theuns, J., et al., Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 78(6): 936-46 (2006).
54. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ, et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down Syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis 3: 16-32 (1996).
55. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 37(3): 294-9 (1995).
56. Mann DM, Iwatsubo T. Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). Neurodegeneration 5(2): 115-20 (1996).
57. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Arch Neurol, 52: 379-391 (1995).
58. Hyman BT, West HL, Rebeck GW, Lai F, Mann DM. Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol 52: 373-378 (1995).
59. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: A regional quantitative analysis. Experimental Neurology 150: 296-304 (1998).
60. Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, et al. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Patho 156(2): 489-499 (2000).
61. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging 25(10): 1263-72 (2004).
62. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157: 277-286 (2000).
63. Fonseca MI, Head E, Velazquez P, Cotman CW, Tenner AJ. The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age. Exp Neurol 157(2): 277-88(1999).
64. Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC, Lott IT, et al. Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. Exp Neurol 163(1): 111-22 (2000).
65. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis 8(5): 792-806 (2001).
66. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3 (pE), in senile plaques. Neuron 14: 457 (1995).
67. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 563(1-3): 191-6 (2004).
68. Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol 183(2): 369-81 (2013).
69. Mehta, P., et al. Incrased Plasma Pyroglutamate-3 Amyloid Beta Protein Levels in Older Persons with Down Syndrome (DS). Neurology 82(10): S38.004 (2014).
70. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ. Fulllength amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol 149(6): 1823-30 (1996).
71. Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, Lee VM. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol 112(2): 163-74 (2006).
72. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Aminoand carboxyl-terminal heterogeneity of b-amyloid peptides deposited in human brain. Neurosci Lett 215: 173-176 (1996).
73. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, et al. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 271(52): 33623-31 (1996).
74. Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 11(6): 710-7 (2015)
75. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 5: 17 (2013).
76. Provenzano FA Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Narkhede A, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol 70(4): 455-61 (2013).
77. Akoudad S, de Groot M, Koudstaal PJ, van der Lugt A, Niessen WJ, Hofman A, et al. Cerebral microbleeds are related to loss of white matter structural integrity. Neurology 81(22): 1930-7 (2013).
78. Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain 130(Pt 3): 731-9 (2007).
79. Lo RY, JagustWJ, I. Alzheimer's Disease Neuroimaging, Vascular burden and Alzheimer disease pathologic progression. Neurology 79(13): 1349-55 (2012).
80. Murdoch JC, Rodger JC, Rao SS, Fletcher CD. Dunningham, M.G., Down's syndrome: an atheroma-free model?. Br Med J 2(6081): 226-228 (1977).
81. Rodrigues, A.N., et al., Stiffness of the large arteries in individuals with and without Down syndrome. Vasc Health Risk Manag 7: p. 375-81 (2011).
82. Brattstrom L, Englund E, Brun A. Does Down syndrome support homocysteine theory of arteriosclerosis. Lancet 14(8529): 391-392 (1987).
83. Yla-Herttuala S, Luoma J, Nikkari T, Kivimaki T. Down's syndrome and atherosclerosis. Atherosclerosis 76(2-3): 269-272 (1989).
84. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 18(2): 311-24 (1987).
85. Ikeda S, Tokuda T, Yanagisawa N, Kametani F, Ohshima T, Allsop D. et al., Variability of beta-amyloid protein deposited lesions in Down's syndrome brains. Tohoku J Exp Med 1174(3): 189-98 (1994).
86. Lai F, Williams MD. A prospective study of Alzheimer Disease in Down Syndrome. Arch Neurol 46: 849-853 (1989).
87. Belza MG, Urich H. Cerebral amyloid angiopathy in Down's syndrome. Clin Neuropathol 5(6): 257-60 (1986).
88. Mendel T, Bertrand E, Szpak GM, Stępień T, Wierzba-Bobrowicz T. Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome-a case report. Folia Neuropathol 48(3): 206-11 (2010).
89. Naito KS, Sekijima Y, Ikeda S. Cerebral amyloid angiopathyrelated hemorrhage in a middle-aged patient with Down's syndrome. Amyloid 15(4): 275-7 (2008).
90. McCarron MO, Nicoll JA, Graham DI. A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors. J Neurol Neurosurg Psychiatry 65(3): 405-6 (1998).
91. Donahue JE, Khurana JS, Adelma L S. Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy. Acta Neuropathol 95(2): 213-6 (1998).
92. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88(4): 640-51 (2014).
93. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 81(1): 1-8 (2002).
94. Melchor JP, Pawlak R, Stickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-b (Ab) degradation and inhibits Ab-induced neurodegeneration. J Neurosci 23(26): 8867-8871 (2003).
95. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 32: 177-180 (2001).
96. Englund H, Anneren G, Gustafsson J, Wester U, Wiltfang J, Lannfelt L, et al. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dement Geriatr Cogn Disord 24(5): 369-74 (2007).
97. Tamaoka A, Sekijima Y, Matsuno S, Tokuda T, Shoji S, Ikeda SI.et al. Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome. Ann Neurol 46(6): 933 (1999).
98. Tapiola T, Soininen H, Pirttila T. CSF tau and Ab42 levels in patients with Down's syndrome. Neurology 56: 979-980 (2001).
99. Portelius E, Soininen H, Andreasson U, Zetterberg H, Persson R, Karlsson G, Blennow K, et al, Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. Neurodegener Dis 14(2): 98-106 (2014).
100. Portelius E, Holtta M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, Herukka SK, et al. Altered cerebrospinal fluid levels of amyloid beta and amyloid precursor-like protein 1 peptides in Down's syndrome. Neuromolecular Med 16(2): 510-6 (2014).
101. Blennow K, Zetterberg H. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am 97(3): 369-76 (2013).
102. Tokuda T, Fukushima T, Ikeda S, Sekijima Y, Shoji S, Yanagisawa N, Tamaoka A, et al. Abeta1-42(43) are elevated in Down's syndrome. Ann Neurol 41(2): 271-3 (1997).
103. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM. Increased plasma amyloid b protein 1-42 levels in Down syndrome. Neuroscience Lett 241: 13-16 (1998).
104. Cavani S, Tamaoka A, Moretti A, Marinelli L, Angelini G, Di Stefano S, et al. Plasma levels of amyloid b 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet 95: 224-228 (2000).
105. Schupf, N., et al., Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301(3): 199-203 (2001).
106. Mehta PD, et al. Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome. Neurosci Lett 342(3): 155-8 (2003).
107. Head E, et al. Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 23(3): 399-409 (2011).
108. Bartha JL, Soothill PW. Plasma amyloid beta protein 1-42 levels in fetuses with Down syndrome. Early Hum Dev 81(4): 351-4 (2005).
109. Schupf, N., et al., Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology 75(18): 1639-44 (2010).
110. Matsuoka Y, et al. The relationship of plasma Abeta levels to dementia in aging individuals with down syndrome. Alzheimer Dis Assoc Disord 23(4): 315-8 (2009).
111. Jones EL, et al. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett 451(2): 162-4 (2009).
112. Prasher VP, et al. Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry (2009).
113. Coppus AM, et al., Plasma beta amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol Aging 33(9): 1988-94 (2012).
114. Iqbal K, et al., Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118(1): 53-69 (2009).
115. Cardenas AM, et al. Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome. Arch Med Res 43(8): 645-54 (2012).
116. Wegiel, J., et al., Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol 70(1): 36-50 (2011).
117. Harris CD, Ermak G, Davies KJ. RCAN1-1L is overexpressed in neurons of Alzheimer's disease patients. FEBS J 274(7): 1715-24 (2007).
118. Kimura R, et al., The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16(1): 15-23 (2007).
119. Lloret A, et al., Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis 27(4): 701-9 (2011).
120. Head E, et al. Parallel Compensatory and Pathological events Associated with Tau Pathology in Middle Aged Individuals with Down Syndrome. J Neuropath Exp Neurol 62(9): 917-926 (2003).
121. Molina L, et al., Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport 10(17): 3491-5 (1999).
122. Brooksbank BW, Martinez M, Balazs R. Altered composition of polyunsaturated fatty acyl groups in phosphoglycerides of Down's syndrome fetal brain. J Neurochem 44(3): 869-74 (1985).
123. Odetti P, et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 243(3): 849-51 (1998).
124. Pratico D, et al. Down's syndrome is associated with increased 8, 12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 48(5): 795-8 (2000).
125. Di Domenico F, et al. Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med 71C: 270-280 (2014).
126. Di Domenico F, et al. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta 1832(8): 1249-59 (2013).
127. Butterfield DA, et al. Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J 463(2): 177-89 (2014).
128. Busciglio J, et al. Altered metabolism of the amyloid b precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33: 677-688 (2002).
129. Tiano L, Busciglio J. Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10) ? Biofactors 37(5): 386-92 (2011).
130. Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J. Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab 17(1): 132-40 (2013).
131. Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis 20(2): S293-310 (2010).
132. Nunomura A, Perry G, Pappolla M, Friedland RP, Hirai K, Chiba S, et al. Neuronal oxidative stress precedes amyloid-b deposition in Down syndrome. J Neuropath Exp Neurol 59(11): 1011-1017 (2000).
133. Akiyama, H., Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21(3): 383-421 (2000).
134. Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, et al. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res Rev 59(1): 155-63 (2008).
135. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77(1): 43-51 (2015).
136. Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr Gerontol Geriatr Res 2012: 170276 (2012).
137. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribbs DH, et al. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol Dis 8(2): 252-65 (2001).
138. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin I and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 86: 7611-7615 (1989).
139. Xue QS, Streit WJ. Microglial pathology in Down syndrome. Acta Neuropathol 122(4): 455-66 (2011).
140. Colton C, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 9(2): 174-91 (2010).
141. Mann DM. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing Dev 23(1): 73-94 (1983).
142. German, DC, Manaye KF, White CL 3rd, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32(5): 667-76 (1992).
143. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2): 555-63 (2011).
144. Sadowski M, Wisniewski HM, Tarnawski M, Kozlowski PB, Lach B, Wegiel J. Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology. Acta Neuropathol (Berl) 97(2): 156-64 (1999).
145. Mann DM, Yates PO, Marcyniuk B, Ravindra CR. Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age. Quantitative comparisons with younger Down's patients and patients with Alzheimer's disease. J Neurol Sci 80(1): 79-89 (1987).
146. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol 18(3): 310-3 (1985).
147. Gold BT, Johnson NF, Powell DK, Smith CD. White matter integrity and vulnerability to Alzheimer's disease: preliminary findings and future directions. Biochim Biophys Acta 1822(3): 416-22 (2012).
148. Tokuda T, Tanaka K, Kametani F, Ikeda S, Yanagisawa N. Secretory form of beta-amyloid precursor protein is much abundantly contained in the cerebral white matter in human brain. Neurosci Lett 175(1-2): 33-6 (1994).
149. Mattiace LA, Kress Y, Davies P, Ksiezak-Reding H, Yen SH, Dickson DW. Ubiquitin-immunoreactive dystrophic neurites in Down's syndrome brains. J Neuropathol Exp Neurol 50(5): 547-59 (1991).
150. Nishimura A, Sawada S, Ushiyama I, Yamamoto Y, Nakagawa T, Tanegashima A, Lectin-histochemical detection of degenerative glycoconjugate deposits in human brain. Forensic Sci Int 113(1-3): 265-9 (2000).
151. Palminiello S, Jarzabek K, Kaur K, Walus M, Rabe A, Albertini G, et al. Upregulation of phosphorylated alphaB-crystallin in the brain of children and young adults with Down syndrome. Brain Res 1268: 162-73 (2009).
152. Dowjat WK, Adayev T, Kuchna I, Nowicki K, Palminiello S, Hwang YW, et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci Lett 413(1): 77-81 (2007).
153. Jansen J, Rozeboom W, Penning C, Evenhuis HM. Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability. J Intellect Disabil Res 57(7): 681-5 (2013).
154. Draheim CC, Geijer JR, Dengel DR. Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome. Am J Cardiol 106(10): 1512-6 (2010).
155. Morrison RA, McGrath A, Davidson G, Brown JJ, Murray GD, Lever AF. Low blood pressure in Down's syndrome, A link with Alzheimer's disease? Hypertension 28(4): 569-75 (1996).
156. Pueschel SM, Craig WY, Haddow JE. Lipids and lipoproteins in persons with Down's syndrome. J Intellect Disabil Res 36(Pt 4): 365-369 (1992).
157. Head E, Lott IT, Patterson D, Doran E, Haier RJ. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J Alzheimers Dis 11(1): 61-76 (2007).
158. Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, et al. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 61(12): 1673-9 (2003).
159. Martin SB, Dowling AL, Lianekhammy J, Lott IT, Doran E, Murphy MP, et al. Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease. J Alzheimers Dis 42(3): 767-75 (2014).